Prop 65 Compliance Influences Retailers’ Demands
This article was originally published in The Tan Sheet
“In some cases, they are asking the manufacturer to remove a certain chemical from products,” Christopher Guay, P&G’s Prop 65 compliance point person, says at a CHPA conference.
You may also be interested in...
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.